Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group
Fiche du document
27 mai 2024
- handle: 10670/1.k1r5zg
- inserm-04639662
- doi: 10.1016/j.annonc.2024.04.005
- PUBMED: 38834388
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.annonc.2024.04.005
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/38834388
info:eu-repo/semantics/OpenAccess
Mots-clés
next-generation sequencing (NGS) advanced cancer precision medicine ESCAT next-generation sequencing (NGS) advanced cancer precision medicine ESCAT -bio]/CancerSujets proches
Carcinoma Cancers Malignancy (Cancer) Malignant tumorsCiter ce document
M.F. Mosele et al., « Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group », HALSHS : archive ouverte en Sciences de l’Homme et de la Société, ID : 10.1016/j.annonc.2024.04.005
Métriques
Partage / Export
Résumé
Background: Advancements in the field of precision medicine have prompted the European Society for Medical Oncology (ESMO) Precision Medicine Working Group to update the recommendations for the use of tumour next-generation sequencing (NGS) for patients with advanced cancers in routine practice.Methods: The group discussed the clinical impact of tumour NGS in guiding treatment decision using the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) considering cost-effectiveness and accessibility.Results: As for 2020 recommendations, ESMO recommends running tumour NGS in advanced non-squamous non-small-cell lung cancer, prostate cancer, colorectal cancer, cholangiocarcinoma, and ovarian cancer. Moreover, it is recommended to carry out tumour NGS in clinical research centres and under specific circumstances discussed with patients. In this updated report, the consensus within the group has led to an expansion of the recommendations to encompass patients with advanced breast cancer and rare tumours such as gastrointestinal stromal tumours, sarcoma, thyroid cancer, and cancer of unknown primary. Finally, ESMO recommends carrying out tumour NGS to detect tumour-agnostic alterations in patients with metastatic cancers where access to matched therapies is available.Conclusion: Tumour NGS is increasingly expanding its scope and application within oncology with the aim of enhancing the efficacy of precision medicine for patients with cancer.